BioSyent (RX) News Today C$11.30 +0.39 (+3.57%) (As of 11/20/2024 05:34 PM ET) Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesInsider Trades All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period BioSyent Inc. (BIOYF)November 21 at 6:41 AM | finance.yahoo.comBioSyent (CVE:RX) Stock Crosses Below 50-Day Moving Average - Time to Sell?BioSyent (CVE:RX) Stock Price Crosses Below Fifty Day Moving Average - Should You Sell?November 21 at 4:11 AM | marketbeat.comBioSyent Inc.November 13, 2024 | wsj.comBioSyent (CVE:RX) Stock Passes Below Fifty Day Moving Average - What's Next?BioSyent (CVE:RX) Stock Crosses Below 50 Day Moving Average - What's Next?November 13, 2024 | marketbeat.comBioSyent (CVE:RX) Sets New 1-Year High - Should You Buy?BioSyent (CVE:RX) Hits New 52-Week High - Should You Buy?November 4, 2024 | marketbeat.comBioSyent (CVE:RX) Stock Passes Above Fifty Day Moving Average - Here's WhyBioSyent (CVE:RX) Stock Price Crosses Above Fifty Day Moving Average - Should You Sell?October 31, 2024 | marketbeat.comBioSyent Inc.'s (CVE:RX) Stock Is Going Strong: Is the Market Following Fundamentals?October 24, 2024 | finance.yahoo.comBioSyent (CVE:RX) Share Price Passes Above 50-Day Moving Average - Here's WhyBioSyent (CVE:RX) Stock Passes Above 50 Day Moving Average - What's Next?October 12, 2024 | marketbeat.comBioSyent (CVE:RX) Hits New 52-Week High at $11.49BioSyent (CVE:RX) Hits New 52-Week High at $11.49October 3, 2024 | marketbeat.comSaatva Rx Mattress Review 2024: A Luxury Bed Designed for People With Chronic Health ConditionsOctober 1, 2024 | cnet.comShould You Be Adding BioSyent (CVE:RX) To Your Watchlist Today?September 26, 2024 | finance.yahoo.comBioSyent Inc. to Post FY2024 Earnings of $0.59 Per Share, Bloom Burton Forecasts (CVE:RX)BioSyent Inc. (CVE:RX - Free Report) - Research analysts at Bloom Burton increased their FY2024 earnings estimates for BioSyent in a research report issued to clients and investors on Monday, September 23rd. Bloom Burton analyst D. Martin now anticipates that the company will post earnings of $0.September 25, 2024 | marketbeat.comInsider Selling: BioSyent Inc. (CVE:RX) Director Sells 2,320 Shares of StockSeptember 24, 2024 | insidertrades.comBioSyent Announces Agreement to Purchase Tibelia® (tibolone) AssetsSeptember 20, 2024 | finance.yahoo.comBioSyent Inc. (CVE:RX) Insider FAX Capital Corp. Sells 500,000 SharesSeptember 4, 2024 | insidertrades.comInsider Selling: BioSyent Inc. (CVE:RX) Insider Sells 500,000 Shares of StockBioSyent Inc. (CVE:RX - Get Free Report) insider FAX Capital Corp. sold 500,000 shares of the company's stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of C$10.05, for a total transaction of C$5,025,000.00.September 3, 2024 | marketbeat.comBioSyent (CVE:RX) Has Announced A Dividend Of CA$0.045August 30, 2024 | finance.yahoo.comBioSyent Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS In LineAugust 28, 2024 | finance.yahoo.comBioSyent (CVE:RX) Hits New 12-Month High at $11.45BioSyent (CVE:RX) Hits New 52-Week High at $11.45August 27, 2024 | marketbeat.comBioSyent (CVE:RX) Stock Price Passes Above 50 Day Moving Average of $9.94BioSyent (CVE:RX) Stock Passes Above 50-Day Moving Average of $9.94August 15, 2024 | marketbeat.comBioSyent (CVE:RX) Shares Cross Above 50 Day Moving Average of $9.83BioSyent (CVE:RX) Shares Pass Above 50-Day Moving Average of $9.83August 7, 2024 | marketbeat.comBiosyent: Stocks Overvalued by Analyst Consensus on TSX-V (RX)August 4, 2024 | theglobeandmail.comBioSyent (CVE:RX) Stock Price Crosses Above 50 Day Moving Average of $9.50BioSyent (CVE:RX) Stock Crosses Above 50 Day Moving Average of $9.50July 19, 2024 | marketbeat.comInsider Selling: BioSyent Inc. (CVE:RX) Senior Officer Sells 1,755 Shares of StockJune 22, 2024 | insidertrades.comBioSyent (CVE:RX) Hits New 1-Year High at $9.90BioSyent (CVE:RX) Sets New 12-Month High at $9.90June 20, 2024 | marketbeat.comInsider Selling: BioSyent Inc. (CVE:RX) Director Sells 1,522 Shares of StockJune 18, 2024 | insidertrades.comBioSyent (CVE:RX) Hits New 12-Month High at $9.40BioSyent (CVE:RX) Sets New 52-Week High at $9.40June 12, 2024 | marketbeat.comBioSyent (CVE:RX) Sets New 1-Year High at $9.32BioSyent (CVE:RX) Reaches New 12-Month High at $9.32May 29, 2024 | marketbeat.comBioSyent (CVE:RX) Could Be A Buy For Its Upcoming DividendMay 26, 2024 | finance.yahoo.comBloom Burton Comments on BioSyent Inc.'s FY2024 Earnings (CVE:RX)BioSyent Inc. (CVE:RX - Free Report) - Investment analysts at Bloom Burton boosted their FY2024 EPS estimates for shares of BioSyent in a research note issued to investors on Tuesday, May 21st. Bloom Burton analyst D. Martin now expects that the company will earn $0.55 per share for the year, upMay 23, 2024 | marketbeat.comQ2 2024 EPS Estimates for BioSyent Inc. Boosted by Analyst (CVE:RX)BioSyent Inc. (CVE:RX - Free Report) - Equities research analysts at Bloom Burton upped their Q2 2024 EPS estimates for BioSyent in a research note issued on Tuesday, May 21st. Bloom Burton analyst D. Martin now anticipates that the company will earn $0.13 per share for the quarter, up from theirMay 22, 2024 | marketbeat.comBioSyent (CVE:RX) Has Affirmed Its Dividend Of CA$0.045May 21, 2024 | finance.yahoo.comBioSyent (CVE:RX) Stock Passes Above Fifty Day Moving Average of $8.59BioSyent (CVE:RX) Stock Crosses Above 50-Day Moving Average of $8.59May 18, 2024 | marketbeat.comBioSyent (RX) Scheduled to Post Quarterly Earnings on ThursdayBioSyent (CVE:RX) will be releasing earnings after the market closes on Thursday, May 16, Zacks reports.May 10, 2024 | marketbeat.comIncreases to CEO Compensation Might Be Put On Hold For Now at BioSyent Inc. (CVE:RX)May 10, 2024 | finance.yahoo.comAMD RDNA 4: Everything we know about the RX 8000 seriesMay 9, 2024 | msn.comInsider Buying: BioSyent Inc. (CVE:RX) Insider Purchases 5,100 Shares of StockMay 9, 2024 | insidertrades.comBioSyent Inc.: BioSyent Announces Extension of RepaGyn and Proktis-M AgreementApril 16, 2024 | finanznachrichten.deBioSyent Inc.'s (CVE:RX) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?April 4, 2024 | finance.yahoo.comFeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Ninth Consecutive YearApril 3, 2024 | markets.businessinsider.comBioSyent Inc.: BioSyent Releases Financial Results for Fourth Quarter and Full Year 2023March 21, 2024 | finanznachrichten.deEarnings call: BioSyent Inc. reports robust growth in Q4 and FY 2023March 16, 2024 | uk.investing.comBioSyent Named to 2024 TSX Venture 50February 21, 2024 | markets.businessinsider.comRX:CA BioSyent Inc.February 17, 2024 | seekingalpha.comBioSyent (CVE:RX) Stock Price Crosses Above Fifty Day Moving Average of $8.73BioSyent (CVE:RX) Stock Crosses Above 50 Day Moving Average of $8.73February 16, 2024 | marketbeat.comBioSyent (CVE:RX) Share Price Crosses Below 50 Day Moving Average of $8.70BioSyent (CVE:RX) Shares Cross Below 50-Day Moving Average of $8.70February 8, 2024 | marketbeat.comBioSyent Declares First Quarter 2024 DividendFebruary 6, 2024 | markets.businessinsider.comIs It Smart To Buy BioSyent Inc. (CVE:RX) Before It Goes Ex-Dividend?November 24, 2023 | finance.yahoo.comBioSyent Announces the Availability of Gelclair® in CanadaNovember 20, 2023 | finance.yahoo.comBloom Burton Believes Biosyent (RX) Won’t Stop HereNovember 20, 2023 | markets.businessinsider.com Get BioSyent News Delivered to You Automatically Sign up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter. Email Address Trump won. Buy this coin now. (Ad)Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin. RX Media Mentions By Week RX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RX News Sentiment▼0.000.46▲Average Medical News Sentiment RX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RX Articles This Week▼20▲RX Articles Average Week Get BioSyent News Delivered to You Automatically Sign up to receive the latest news and ratings for RX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Canopy Growth News Cipher Pharmaceuticals News Aurora Cannabis News Organigram News Cardiol Therapeutics News HLS Therapeutics News Medexus Pharmaceuticals News MediPharm Labs News Charlotte's Web News Decibel Cannabis News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (CVE:RX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioSyent Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioSyent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
